Low dose aspirin versus low dose aspirin plus omega 3 versus low molecular weight heparin in treatment of unexplained recurrent miscarriage
Keywords:
Miscarriage, Aspirin, Omega 3, LMWHAbstract
Introduction: recurrent miscarriages are the loss of 3 or more consecutive pregnancies before the 20th week of gestation. It is classified into primary and secondary. Objective: to evaluate the effectiveness of low dose aspirin vs. low dose aspirin and omega 3 vs. LMWH in treatment of unexplained recurrent miscarriage. Materials and methods: This comparative prospective research was conducted on 60 1st trimester pregnant female with a history of two or more unexplained spontaneous consecutive abortion aged from 18 to 36 years old with gestational age (5-7 weeks) and single intrauterine pregnancy. Patients were subdivided equally into 3 groups: Group A: received a daily dose of 75mg of aspirin, group B: received a daily dose of 75 mg of aspirin in addition to 300mg of omega -3 fatty acids and group C: received a daily dose of 4000 IU of enoxaparin. Results: There was an insignificant difference in pregnancy outcome among the three groups. 12 (60%) cases in group A, 15 (75%) cases in group B and 14 cases in group C completed 20 weeks of pregnancy.
Downloads
References
Cadavid, A. P. (2017). Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol, 8, 261.
Coletta, J. M., Bell, S. J., & Roman, A. S. (2010). Omega-3 Fatty acids and pregnancy. Rev Obstet Gynecol, 3(4), 163-171.
El Hachem, H., Crepaux, V., May-Panloup, P., Descamps, P., Legendre, G., & Bouet, P. E. (2017). Recurrent pregnancy loss: current perspectives. Int J Womens Health, 9, 331-345. doi:10.2147/ijwh.S100817
Elmahashi, M. O., Elbareg, A. M., Essadi, F. M., Ashur, B. M., & Adam, I. (2014). Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. BMC Res Notes, 7(1), 1-4.
Ford, H. B., & Schust, D. J. (2009). Recurrent pregnancy loss: etiology, diagnosis, and therapy. Rev Obstet Gynecol, 2(2), 76-83.
Diniari, N. K. S., & Aryani, L. N. A. (2022). Characteristics and pharmacological treatment options of delirium patients treated at Sanglah Central General Hospital . International Journal of Health & Medical Sciences, 5(1), 37-43. https://doi.org/10.21744/ijhms.v5n1.1835
Grandone, E., Tiscia, G. L., Mastroianno, M., Larciprete, G., Kovac, M., Tamborini Permunian, E., . . . Margaglione, M. (2021). Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. Hum Reprod, 36(8), 2083-2090. doi:10.1093/humrep/deab153
Nazari, Z., Ghaffari, J., & Ebadi, A. (2015). Comparison of the effect of aspirin and heparin with or without intravenous immunoglobulin in treatment of recurrent abortion with unknown etiology: A clinical study. J Nat Sci Biol Med, 6(1), 17-21. doi:10.4103/0976-9668.166054
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949
Papadakis, E., Pouliakis, A., Aktypi, Α., Christoforidou, A., Kotsi, P., Αnagnostou, G., . . . Grouzi, E. (2019). Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature. Thromb J, 17, 23. doi:10.1186/s12959-019-0213-9
Wojcieszek, A. M., Shepherd, E., Middleton, P., Lassi, Z. S., Wilson, T., Murphy, M. M., . . . Flenady, V. (2018). Care prior to and during subsequent pregnancies following stillbirth for improving outcomes. Cochrane Database Syst Rev, 12(12), 12203. doi:10.1002/14651858.CD012203.pub2
Yuksel, H., Kayatas, S., Boza, A. T., Api, M., Ertekin, A. A., & Cam, C. (2014). Low molecular weight heparin use in unexplained recurrent miscarriage. Pak J Med Sci, 30(6), 1232-1237. doi:10.12669/pjms.306.5477
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
